Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase III Attain-Maintain trial with ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly and Co. disclosed positive top-line data from the phase III Attain-Maintain trial with orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist. The compound was tested for ...

In an announcement Monday, Nov. 3, the Indianapolis-based pharmaceutical company said the new site will manufacture its weight-loss pill, orforglipron, and other oral medicines. Lilly expects to ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Eli Lilly has developed artificial intelligence models that can help predict the behavior of potential drug candidates, based on the data the drugmaker has collected over the last two decades and at ...

Kernal Biologics, Inc., a venture-backed therapeutics company developing novel therapeutics to program human cells directly inside the body, today announced its relocation to Lilly Gateway Labs (LGL) ...